Bull case
Aura Biosciences is on track with its clinical development plans and has potential for positive results from its ongoing Phase 3 CoMpass trial for bel-sar, with robust statistical powering assumptions and strong alignment with regulatory and clinical endpoints. The completed enrollment of 108 patients provides a buffer against potential patient attrition and the potential for CoMpass to read out positively across different real-world effect sizes beyond the observed Phase 2 data. With a healthy cash position and upcoming data readouts, the company has potential for positive stock growth in the long-term, particularly with the potential for pricing power in a rare disease setting and opportunities for label expansion in other ocular indications. Investors should look for data readouts and durable reductions in recurrence rates in bladder cancer as key value inflection points.